International Journal of Clinical Oncology

, Volume 13, Issue 1, pp 66–70

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

  • Magnus Rizell
  • Mats Andersson
  • Christian Cahlin
  • Larsolof Hafström
  • Michael Olausson
  • Per Lindnér
Original Article

DOI: 10.1007/s10147-007-0733-3

Cite this article as:
Rizell, M., Andersson, M., Cahlin, C. et al. Int J Clin Oncol (2008) 13: 66. doi:10.1007/s10147-007-0733-3

Abstract

Background

Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease. Sirolimus is used in the transplantation setting as an immunosuppressive agent, but it also possesses antiproliferative and antiangiogenic properties. The objective of the study was to evaluate the effect of sirolimus on HCC and CCC.

Methods

In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC. Sirolimus was administered once daily by mouth, with the dose adjusted to a serum trough level between 4 and 15 μg/ml. Tumor response was evaluated by computed tomography (CT) or magnetic resonance imaging (MRI), according to the Response Evaluation Criteria in Solid Tumors (RECIST), every third month. Secondary measures were overall survival, time to tumor progression, tumor markers, and side effects.

Results

Of the patients with HCC, one had partial remission (PR) and fi ve patients had stable disease (SD) at 3 months. Of the patients with CCC, three had SD. The median survival for patients with HCC was 6.5 months (range, 0.2–36 months) and that for patients with CCC was 7 months (range, 2.6–35 months).

Conclusion

Treatment of HCC and CCC with sirolimus can induce temporary PD or SD. This pilot study indicates that sirolimus might be a promising drug for this treatment, but further clinical studies elucidating the biological effects are advocated.

Key words

Primary liver cancerHepatocellular cancerCholangiocellular cancerSirolimus mTOR inhibitor

Copyright information

© Japan Society of Clinical Oncology 2008

Authors and Affiliations

  • Magnus Rizell
    • 1
  • Mats Andersson
    • 2
  • Christian Cahlin
    • 1
  • Larsolof Hafström
    • 1
  • Michael Olausson
    • 1
  • Per Lindnér
    • 1
  1. 1.Department of Surgery, Transplantation and Liver Surgery ServiceSahlgrenska University HospitalGoteborgSweden
  2. 2.Department of RadiologySahlgrenska University HospitalGöteborgSweden